Tag: Passeo-18 Lux
New data on Biotronik’s Passeo-18 Lux DCB presented at LINC 2022
Biotronik recently announced the presentation of two studies on the performance of its drug-coated balloon (DCB) catheter Passeo-18 Lux at the Leipzig Interventional Course (LINC)...
BIOPACT head-to-head non-inferiority randomised controlled trial completes enrolment
Biotronik is proud to announce the completion of enrolment of the investigator-initiated BIOPACT randomised controlled trial (RCT). This non-inferiority study evaluates the safety and...
BIOLUX AV trial demonstrates safety and efficacy of Passeo-18 Lux DCB...
Recent data from the investigator-initiated, randomised controlled trial (RCT), BIOLUX AV, showed that the treatment of dysfunctional haemodialysis access with Biotronik's Passeo-18 Lux drug-coated...
BIOPACT-RCT set to compare Passeo-18 Lux and IN.PACT Admiral DCBs in...
iD3 Medical has announced that it has received approval in Belgium to initiate a randomised controlled trial, BIOPACT-RCT: a physician-initiated multicentre trial evaluating the...
Passeo-18 Lux DCB remains safe and effective at two years with...
Two-year data on the Passeo-18 Lux drug-coated balloon (DCB; Biotronik) continue to validate its safety and effectiveness in intra-inguinal arteries. Gunnar Tepe from the...
Encouraging results for the Biotronik Passeo-18 Lux drug-coated balloon and Pulsar-18...
Interim data presented at the 2017 Leipzig Interventional Course (LINC; 24-27 January, Leipzig, Germany) has demonstrated encouraging results for Biotronik dedicated lower limb intervention portfolio.
“Currently...